Fig. 5.

Adaptive immunity inhibits tumor growth. a The time sequence for the transplant experiments where transplantation of 5 × 10⁶ TCD-BMC preceded a tumor challenge (subcutaneous implantation of 10⁶ Neuro-2a cells). b Comparative growth rates in of Neuro-2a cells in mice allografted (H2 K^b → H2K^a) after tumor implantation (Tu pre-allo BMT), and implantation of tumors at 2 weeks (n = 5), 3 weeks (n = 9) and 4 weeks (n = 11) after allogeneic transplantation (post-BMT). c Comparative growth rates in of Neuro-2a cells in mice grafted with syngeneic TCD-BMC (H2K^a → H2K^a) after tumor implantation (Tu pre-syn BMT), and implantation of tumors at 3 and 4 weeks (n = 6) after syngeneic transplantation (post-BMT). d Tumor size at 30 days after subcutaneous implantation of 10⁶ Neuro-2a cells in mice with syngeneic and allogeneic BMT. Tumors were implanted 5 days before transplantation (pre-BMT) or 4 weeks after transplantation (post-BMT). e Splenic lymphocytes from naïve B6 (n = 12) and A/J mice (n = 5) and A/J mice bearing subcutaneous tumors (n = 6) were stimulated with ConA for 5 days in culture and proliferation was determined from CFSE dilution. The data represent the ratio between control responders and incubation with the soluble fraction of Neuro-2a tumor lysate